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42 days. Specimens were collected at days 1,3,7,21,42,
and 90. IH and SMCp were measured at the fistula site as
well as in the artery and vein proximal and distal to the
fistula.
Results: IH was first noted at day 3 and significantly
increased through day 90 at all locations in the non-
oxygen supplemented groups. There was no significant
IH noted in the O2 supplemented groups at any location
or any time point Table). SMCp was noted at Day 3
through Day 21 in the non-oxygen supplemented group
while almost no SMCp was noted in the O2 supple-
mented groups at any location or timepoint.
Conclusions: Without O2 supplementation SMCp
begins at day 3 and is no longer noted at day 21 after
creation of an AVF while IH begins by day 3 and increases at
least through day 90 after creation of an AVF. 42 days of 30%
supplementalO2 inhibits both IH and SCMp after creation of
an AVF. This data suggests a role for short-term administra-
tion of low-dose O2 to prevent both IH and SMCp after
creation of an AVF prolonging fistula patency and function.
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Objectives: Treatment options for critical limb isch-
emia (CLI) are limited. Recent evidence has suggested
that even with successful revascularisation, patients often
show little functional improvement. This has been attrib-
uted to a musculopathy that occurs in CLI. Myogenic
progenitor satellite cells (SCs) provide skeletal muscle
with an intrinsic ability to regenerate. It has been shown
that there is an increase in SCs in ischemic muscle,
however their function in ischemia is poorly understood
and we hypothesize that ischemia has a detrimental effect
on SC function.
Methods: Gastrocnemius muscle biopsies were taken
from CLI patients and compared with non ischemic
control biopsies. The phenotypical changes and fre-
quency of satellite cells were investigated using PAX 7
immunohistochemistry and western blot. C2C12 myoblasts
were used in vitro, to investigate the effect of ischemia on
muscle progenitor cell function. Myoblasts were exposed to
simulated ischemia for 24, 48 and 72hrs. Proliferation rates
were assessed using an MTT assay. Differentiation and apo-
ptosis were assessed byMYOD and cleaved caspase 3 western
blotting respectively.
Results: There is an increased expression of PAX 7 in
CLI muscle biopsies, shown by both immunostaining and
western blot analysis, suggesting an increased number of
SCs in ischemic human skeletal muscle (P.05).Myoblasts
cultured in ischemic conditions demonstrated decreased
cell proliferation, reduced myogenic differentiation (de-
creased MYOD expression), and increased apoptosis (in-
creased cleaved caspase 3 expression).
Conclusions: Despite an upregulation of SCs in isch-
emic tissue, their function is suppressed in ischemic condi-
tions and this may be contributing to the poor functional
recovery of patients post revascularisation. Enhancement of
muscle regeneration in ischemiamay be a useful therapeutic
adjunct in the treatment of CLI.
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Objectives: MicroRNAs (miRs) are a class of recently
discovered noncoding endogenous, small RNAs that neg-
atively regulate gene expression. miR-221 is associated with
vascular smooth muscle cell proliferation and inhibition of
apoptosis. We aimed to determine whether miR-221 is
decreased in acutely symptomatic as opposed to stable,
asymptomatic carotid plaques.
Methods: Relative changes in gene expression levels
of miR-221 were compared using a commercial real-time
PCR assay and the 

Ct method. All samples were run in
duplicate; mean and standard error were calculated.
One-way ANOVA with Tukey’s test and Pearson’s cor-
relation were used to determine significance between
groups.
Results: Levels of miR-221were quantified from asymp-
tomatic (n16) and symptomatic (n6) carotid
plaques. In order to capture the acute state of plaque
rupture, patients undergoing urgent CEA (n11) for
acute neurologic symptoms were included. The propor-
tion of miR-221 in urgent compared to asymptomatic
carotid plaques was reduced (.30.16 vs. 1.00.44, P
.039) (see figure). Moreover, a decreasing trend in miR-
221 levels was noted in asymptomatic-to-symptomatic-
to-urgent plaques (R.43, P  .013).
Conclusions: Carotid plaque levels of miR-221 are
decreased in patients presenting with acute neurological
symptoms compared to patients with asymptomatic ca-
rotid disease. As miR-221 levels are decreased in rup-
tured (urgent CEA) carotid plaques, we postulate that
loss of miR-221 may be important in the transition of a
stable to an unstable carotid atherosclerotic plaque and
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